So this is more than just layering in a technology, but rather a fundamental change in the culture and the ways of working. So, one that's central to me is the employment of data science.
Second, there are a couple pieces of science. And I've seen it elsewhere done in different ways.
So, that scope, that continuity is critical.
#Back in focus jnj full#
We allow our therapeutic area heads to cover the full span, from idea on a piece of paper, like what project to start, all the way through the last labeled indication prior to loss of exclusivity. Then in terms of strategy, we are organized quite distinctly from other companies. And so, they are the ones that largely make the difference. You need people that can see around corners, and I'm really proud of the team, the senior team that we've been able to assemble that are our therapeutic area leaders and our heads of our major global functions. The hardest thing to do is to pick a project to be disciplined about not continuing project. And so, what I see is several things that make us quite different.įirst and foremost, I have to emphasize is our senior team. Yes, my role is to run our R&D organization in pharmaceuticals, but I'm also – been a long term student of our industry and really have given a great deal of thought to how we are differentiated. And then, we'll move on to some other questions. Wanted to just get your high level views on what sets – what do you think sets Janssen apart from competitors? Over the years, we've learned about the innovation-based strategy, power of the internal R&D team's deep scientific expertise and source-agnostic approach, but wanted to just hear some of your thoughts to just set a foundation for this discussion. But you're also a veteran in this space and held positions in Merck and Theravance. You've been a big part of that success, being the global head of R&D for the last five years. And like to start off with just – and Janssen has had quite a run, multi-year run outpacing the pharma market growth. I know you and your team had a big event back in November and wanted to dig a little bit deeper into the pharma R&D strategy and pipeline. Thanks so much for participating in our conference this year. We are pleased to kick off our track with Mathai Mammen, the Executive Vice President of Pharmaceuticals, Research and Development of the Janssen franchise within Johnson & Johnson. I'm Josh Jennings from the Cowen medical devices research team, representing my colleagues, Brian Kennedy, Eric Anderson, Michael Jackson and (ph). Mathai Mammen - Executive Vice President, Pharmaceuticals R&D (013469-191218)įor complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.Johnson & Johnson ( NYSE: JNJ) 42nd Annual Cowen Health Care Conference Ma9:10 AM ET In benchtop test using 5‐7mm porcine carotids that compared median burst pressure for HARMONIC ACE®+7 (1419.5 mmHg) and LigaSure™ Advance (670.5 mmHg) (pCheng et al., A systematic review and meta-analysis of Harmonic Focus in thyroidectomy compared to conventional techniques.
0 kommentar(er)
